Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.
Company Guidance
During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Entolimod Development Progress
Transferred two INDs for Entolimod, completed cell line verification, and advanced manufacturing readiness for military countermeasure and stockpile drug.
Financial Position
Cash and cash equivalents increased to $3.5 million from $2 million, with no debt on the balance sheet.
Gross Margin Improvement
Gross margins, excluding inventory reserve, improved to 42% from 35% compared to the previous year.
Tivic Health Systems (TIVC) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TIVC Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 14, 2025
$1.91
$1.50
-21.47%
Aug 14, 2025
$3.50
$3.79
+8.29%
May 15, 2025
$4.32
$4.27
-1.16%
Mar 21, 2025
$3.55
$3.41
-3.94%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tivic Health Systems (TIVC) report earnings?
Tivic Health Systems (TIVC) is schdueled to report earning on Apr 01, 2026, TBA (Confirmed).
What is Tivic Health Systems (TIVC) earnings time?
Tivic Health Systems (TIVC) earnings time is at Apr 01, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.